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Abstract 
Brain MRI is an important tool in the diagnosis and monitoring in multiple sclerosis patients. However, MRI 
alone provides limited information for predicting an individual patient’s disability progression. In part, this 
is because MRI lacks sensitivity and specificity for detecting chronic diffuse and multi-focal inflammation 
mediated by activated microglia/macrophages. The aim of this study was to test for an association between 
18 kDa translocator protein (TSPO) brain positron emission tomography (PET) signal, which arises largely 
from microglial activation, and measures of subsequent disease progression in multiple sclerosis patients. 21 
multiple sclerosis patients (7 with secondary progressive disease and 14 with a relapsing remitting disease 
course) underwent T1- and T2-weighted and magnetization transfer MRI at baseline and after 1 year. PET 
scanning with the translocator protein radioligand [11C]PBR28 was performed at baseline. Brain tissue and 
lesion volumes were segmented from the T1- and T2-weighted MRI and relative [11C]PBR28 uptake in the 
normal -appearing white matter was estimated as a distribution volume ratio (DVR) with respect to a 
caudate pseudo-reference region. Normal appearing white matter distribution volume ratio DVR at baseline 
was correlated with enlarging T2-hyperintense lesion volumes over the subsequent year (ρ=0.59, p=0.01). A 
post hoc analysis showed that this association reflected behaviour in the sub-group of relapsing remitting 
patients (ρ=0.74, p=0.008). By contrast, in the sub-group of secondary progressive patients, microglial 
activation at baseline was correlated with later progression of brain atrophy (ρ=0.86, p=0.04). A regression 
model including the baseline normal -appearing white matter distribution volume ratioDVR, T2 lesion 
volume and normal -appearing white matter magnetization transfer ratio for all of the patients combined 
explained over 90% of the variance in enlarging lesion volume over the subsequent 1 year. Glial activation 
in white matter assessed by translocator protein PET significantly improves predictions of white matter 
lesion enlargement in relapsing remitting patients and greater brain atrophy in secondary progressive disease 
over a period of short -term follow up.  
 
Keywords: multiple sclerosis; microglia; atrophy; translocator protein; positron emission tomography 
Abbreviations: DVR = distribution volume ratio; MTR = magnetization transfer ratio; NAWM = normal 
appearing white matter; PET = positron emission tomography; RRMS = relapsing remitting multiple 
sclerosis; SPMS = secondary progressive multiple sclerosis; TSPO = translocator protein  
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Introduction 
Multiple sclerosis is a chronic inflammatory, demyelinating and neurodegenerative disease of the central 
nervous system leading to progressive neuroaxonal loss and subsequent brain atrophy. Clinically, multiple 
sclerosis typically presents as acute neurological episodes (relapses) with complete or partial recovery 
(relapsing remitting multiple sclerosis or RRMS) with a later stage of progression of disability (secondary 
progressive multiple sclerosis or SPMS). Inflammatory demyelinating white (and grey) matter lesions are 
characteristic of the disease. White matter lesions are visualized on conventional MRI by focal 
hyperintensity on T2-weighted imaging and, when acute, often by gadolinium-contrast enhancement on T1-
weighted imaging. White matter lesions detected by MRI are routinely used to aid diagnosis and monitor 
disease. Combination of the number of new and enlarging T2 lesions with annualized brain atrophy rate 
predicts a large proportion of the variance in short term disability progression for RRMS (Sormani et al., 
2011; Popescu et al., 2013; Sormani et al., 2014). These conventional MRI measures are commonly used as 
early phase clinical trial outcomes (Filippi et al., 1995; Lee et al., 1998). We hypothesize that imaging 
measures of activation of microglia, the innate immune cells of the central nervous system, could predict an 
additional component of the variance in future disease progression with both RRMS and SPMS. 
Histopathologically different types of white matter lesions have been identified (Lucchinetti et al., 2004). 
Acute lesions or those showing peripheral innate immune activation associated with demyelination (so 
called “slowly expanding” lesions) may be those most likely to enlarge over time (Prineas et al., 2001; 
Lucchinetti et al., 2004; Filippi et al., 2012). The latter appear to be characteristic of progressive forms of 
MS. Activated microglial nodules in the white matter that can be found in association with demyelinating 
and damaged axons may precede the appearance of new lesions (Seewann et al., 2009; Singh et al., 2013). 
Direct tests and clinical applications of these findings is limited, however, as conventional MRI lacks 
sensitivity and specificity for detecting the diffuse extra-lesional innate immune inflammation in the white 
matter evident from post -mortem neuropathology (Filippi et al., 2012); radiologically, thes  areas appear as 
normal appearing white matter (NAWM) on conventional MRI (Allen et al., 2001). A challenge for imaging 
in MS thus has been to develop more sensitive and specific measures to better reconcile assessments of 
histopathology made post mortem with imaging measures in vivo. Magnetization transfer imaging, for 
example, enhances the contrast between white matter water molecules associated with macromolecules and 
free water. This increases sensitivity for detection of demyelination and neuroaxonal loss (Schmierer et al., 
2004; Vrenken et al., 2006; Moll et al., 2011).  
Our understanding of the in vivo evolution of innate inflammatory pathology in multiple sclerosis brain 
remains limited, however. This aspect of the immune response has mainly been studied only cross-
sectionally post mortem. The 18 kDa mitochondrial translocator protein can be highly expressed in activated 
microglia and astrocytes (Cosenza-Nashat et al., 2009). In multiple sclerosis, currently available imaging-
pathological correlations suggest that increased radioligand uptake relatively specifically reflects microglial 
activation (Matthews and Datta, 2015; Datta et al., 2016). PET radioligands specific for TSPO have been 
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used to study the distribution and relative magnitude of microglial activation. Clinical TSPO PET studies 
reported higher uptake in grey matter and white matter (NAWM and white matter lesions) in multiple 
sclerosis than in healthy volunteers, although the relationship of TSPO uptake across brain regions within 
individual multiple sclerosis brains was not reported in these studies (Politis et al., 2012; Colasanti et al., 
2014; Herranz et al., 2016). These findings in vivo were obtained using both the first generation and the 
higher affinity second generation TSPO radioligands.  
Increases in lesion load and brain atrophy are strongly correlated with disease progression and worse 
clinical outcomes (Sormani et al., 2014). Here we investigated whether in vivo glial activation assessed 
using [
11
C]PBR28 TSPO PET imaging could be used to predict T2 lesion volume change and brain atrophy 
over the subsequent 1 year and therefore enhance precision in identifying patients at higher risk of 
worsening disease. We explored whether adding magnetization transfer imaging of NAWM as a measure of 
demyelination could further add additional predictive power.  
 
Materials and methods 
Patients 
The study was approved by the West Bromley Research Ethics Committee (Ref No. 14/LO/0445) and the 
UK Administration of Radioactive Substances Advisory Committee. All patients gave written informed 
consent in accordance with the Declaration of Helsinki.  
Patients with a diagnosis of multiple sclerosis according to the revised McDonald criteria (2010) (Polman 
et al., 2011), with EDSS (Expanded Disability Status Scale) up to 7.0 and either a relapsing remitting or a 
secondary progressive disease course were studied (Table 1). Usual care of the patients was not interrupted 
during the period of this observational study and many of the patients were on disease modifying treatments 
(Table 1), but none of the patients had been treated with steroids or experienced a clinical relapse within 3 
months of their scans. Patients who were claustrophic, had metal implants or fragments in their bodies or 
who had received radiation above background exceeding 10 millisieverts in the previous 3 years or women 
who were pregnant or breastfeeding were not eligible to participate, although none of those screened met 
these exclusion criteria and were therefore not excluded.  
MRI scanning was performed at baseline and after 1 year and a PET scan was done at baseline only. The 
same scanner, MRI parameters, and clinical assessment protocols were employed for all participants and 
longitudinal comparisons.  
 
EDSS and neurological assessment 
The clinical history and physical examination, including assessment of EDSS, was completed by the same 
investigator (GD) on every patient subject at the screening visit and after 1 year at the time of follow-up 
MRI scanning for each of the subsequent study visits. The first study visit, at which all the baseline scans 
Formatted: Font color: Red
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were performed, took place within 6 weeks of the screening visit. None of the patients experienced clinical 
events between their screening and baseline scanning visits. A follow-up MRI scan was performed after 12 
months. 
  
TSPO genotyping 
TSPO genotype was assessed using a TaqMan based polymerase chain reaction (Applied Biosystems® 
QuantStudioTM 7) assay specific for the rs6971 polymorphism in the TSPO gene, as previously described 
(Owen et al., 2012). Participants having genotypes associated with low affinity binding were excluded, as 
they show negligible displaceable binding (Owen et al., 2012). For the baseline scans, there were 13 high 
affinity binders and 11 medium affinity binders.  
  
MRI scanning 
MRI scans were performed on a Siemens 3 Tesla Trio scanner (Siemens Healthcare, Erlangen Germany) 
equipped with a 32-channel phased-array head coil. Volumetric T1-weighted MPRAGE images were 
acquired for all patients using a 1 mm isotropic resolution 3D SPACE sequence (repetition time = 2300 ms, 
echo time = 2.98 ms, inversion time =9 00 ms with 256 x 240 x 160mm field of view), before and 5 minutes 
after intravenous gadolinium-chelate administration (0.2 mL/kg Gadoteric Acid, Dotarem®) (Jack et al., 
2008). Volumetric T2-weighted FLAIR (fluid attenuated inversion recovery) images were acquired using a 
1mm isotropic resolution 3D SPACE sequence with a 250 x 250 x 160 mm field of view, echo time = 395 
ms, repetition time = 5 s, inversion time = 1800 ms, turbo factor of 141, 256 x 256 x 160 matrix, and parallel 
imaging factor of 2).  
MTR maps were acquired using a 3D spoiled gradient echo sequence (fast low angle shot [FLASH]). To 
generate a pseudo- proton density weighting (PDw) image, two volumes with 1mm isotropic resolution were 
acquired using 256x246x196 mm field of view, repetition time TR=27 ms, flip angle=5°, a parallel imaging 
factor of 2, 6 echoes acquired using 630Hz/pixel bandwidth with TEs every 1.95ms from 1.95 to 11.7ms). 
Magnetization transfer weighting (MTw) was added using a 12.24ms duration Gaussian radiofrequencyRF 
pulse (flip angle of 540) 2.2 kHz off resonance. MTR maps were calculated from the equation: 
MTR = 100*(SPDw – SMTw)/SPDw 
where SPDw=signal from PDw image and SMTw=signal from MTw image 
 
PET scanning 
PET scanning (Discovery RX PET/CT scanner) was performed with a trans-axial resolution of 5.0 mm, and 
a radial resolution of 5.1 mm. PET data were reconstructed using filtered back projection including 
corrections for attenuation and scatter (based on a low-dose CT acquisition). The dynamic data were binned 
into 26 frames (durations of 8 x 15 s, 3 x 1 min, 5 x 2 min, 5 x 5 min, 5 x 10 min). [
11
C]PBR28 was injected 
as an intravenous bolus over approximately 20 s at the start of a 90 min dynamic PET acquisition. Injected 
Formatted: Font color: Red
Page 5 of 26
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 6
activities for [
11
C]PBR28 ranged from 223.8- 379.6 MBq (335.1+30.9 MBq, n=24). Injected mass for 
different patientsubjects ranged from 1.48 - 8.91 µg (3.35+1.96 µg).  
 
Radioligand synthesis 
Radiosynthesis and quality control was performed on site according to the method of Briard et al. (2008) 
with modification, as previously described, obtaining radiochemical purities of > 95% (Briard et al., 2008).  
 
MRI image and PET kinetic analyses  
T2 FLAIR images were rigidly registered to T1 using FLIRT (FMRIB Software Library v5.0). White matter 
lesions were manually segmented on the registered T2 image using Jim software (Xinapse Systems v7). The 
white matter lesion mask was used for lesion- filling the baseline and follow-up T1 images before 
segmentation into white matter, grey matter, cerebral cortex and cerebrospinal fluid using the FSL tools 
FAST and FIRST (FMRIB Software Library v5.0) (Battaglini et al., 2012). Normalised brain volumes were 
calculated using SIENAX (Smith et al., 2002). For measurement of longitudinal changes in brain volumes, 
the MSmetrix method was used (Jain et al., 2015; Smeets et al., 2016). In brief, the baseline and follow-up 
T1 images were bias corrected, lesion filled, and skull stripped, followed by linear and a non-linear 
registration from baseline to follow-up and visa versa. Voxel-wise differences in volume from the nonlinear 
registration were integrated over the whole brain and grey matter volumes to calculate the changes in 
volume over 1 year, as previously described (Smeets et al., 2016).  
T2 hyperintense white matter lesions were segmented automatically using a previously validated method 
(Jain et al., 2015). Subtraction of the lesion masks from the MRI scans acquired at baseline from that 
acquired after 1 year for each patient subject allowed new or enlarging lesion volumes to be determined. For 
this, a mask of NAWM was created by subtracting a white matter lesion mask dilated by 6mm around its 
edges in 3D from the FAST segmentation of the total white matter and then eroding the resulting mask 
further by 3 mm (Lee et al., 1998).  
The T1 image, NAWM mask and white matter lesion mask and dynamic PET images were used as inputs 
to the MIAKAT software package (www.miakat.org) for kinetic analysis of PET data. Using this software, 
PET images were corrected for patient subject motion using a frame-by-frame realignment algorithm and 
rigid registered to MNI (Montreal Neurological Institute) 2 mm space using SPM5 (Wellcome Trust Centre 
for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) with a mutual information cost function. The Clinical 
Imaging Centre Neuroanatomical Atlas (Tziortzi et al., 2011) was non-linearly deformed into the 
individual’s space, via mapping of T1-weighted MR imaging data, to obtain a personalized anatomical 
parcellation of the brain. This parcellation was used to generate time-activity curves for regions of interest, 
including the thalamus, caudate, NAWM, white matter lesions and (voxel-wise) for whole brain.  
The Logan graphical reference method was used to estimate DVR values from regional and voxel-wise 
time-activity curves using the caudate nucleus as a pseudo-reference region and a linear start time of 35 
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minutes (Logan et al., 1996). With this approach, a distribution volume ratio (DVR) can be estimated from a 
graphical linearization method using dynamic PET measurements from the region of interest C(t) and from a 
reference region C'(t) with an average rate constant for radioligand clearance from tissue-to-plasma of k'2: 
 
In this graph, DVR is the regression slope and the intercept is int'. 
 
Statistical analyses 
Statistical analyses were performed using SPSS software (IBM, SPSS v22). For correlational analyses, the 
Spearman’s correlation coefficient was calculated, unless otherwise stated. Descriptive statistics were 
reported as median and range, unless otherwise stated.  
The proportional increase in volume from baseline T2 lesion volume was less than 10% for almost all 
patients with enlarging T2 lesions, so we considered a 5% increase in volume of enlarging T2 lesions as a 
significant outcome change in constructing a receiver operating characteristic (ROC) with white matter 
DVR as the discriminant. 
Hierarchical linear regression was used to assess separately whole brain atrophy rate, overall T2 lesion 
volume change and enlarging T2 lesion volume. We evaluated 4 different 3 level hierarchical linear 
regression models: 
 
1.  Dependent variable of whole brain atrophy rate (% between baseline and follow-up scan) with EDSS, 
age and gender as covariates (level 1) and independent variables as NAWM DVR controlling for TSPO 
binding status (level 2) followed by baseline T2 lesion volume (level 3). 
2. Dependent variable of overall T2 lesion volume change (mL between baseline and follow-up scan) with 
three levels as above. 
3. Dependent variable of enlarging T2 lesion volume change (mL between baseline and follow-up scan) 
with three levels as above. 
4. Dependent variable of enlarging T2 lesion volume change (mL between baseline and follow-up scan) 
with NAWM DVR controlling for TSPO binding status (level 1), NAWM MTR (level 2) and baseline 
T2 lesion volume (level 3). 
 
For all models, the coefficient of determination (R
2
) was reported for level 1. For each level thereafter 
(level 2 and 3), the contribution of the next level independent of other levels for explaining variance in the 
dependent variable was reported as R2 change values. Where correlations were directly assessed and for post 
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hoc analyses, a correction was made for multiple comparisons (Bonferroni method). A p-value of less than 
0.05 was considered significant for all statistical tests. Receiver operator characteristic (ROC) plots were 
used to assess the accuracy of classifications using the models. 
 
Results 
24 multiple sclerosis patients initially underwent [
11
C]PBR28 PET scanning and MRI at baseline (17 
RRMS and 7 SPMS). Clinical characteristics of the participants are summarised in Table 1. [
11
C]PBR28 
PET imaging characteristics of their white matter and of individual lesions are described relative to white 
matter of matched, healthy volunteers in a recent paper (Datta et al., 2017). Illustrative images are shown in 
Figure 1. One patient from this group was lost to follow-up (A23), one withdrew consent (A9) and one 
declined scanning because of discomfort from side effects of treatment with alemtuzimab (A22). 21 patients 
had a follow-up MRI approximately 1 year (median 12 months, range 11-14 months) after the baseline 
scanning. Of the 21 patients included in the longitudinal analysis (8 men; median age 48 years, range 22–66 
years), 7 had a diagnosis of SPMS and 14 of RRMS. The median baseline EDSS was 4.0 (range, 1.0–7.0) 
and median disease duration was 13 years (range, 1-28 years). 7 patients had a relapse between their 
baseline and follow-up scans (median 0 relapses/year, range 0-1 relapses/year). The EDSS at follow-up did 
not change in 16 patients of the 21 patients (EDSS change: median 0.0, mean 0.2, range 0.0-2.0).  
 
[
11
C]PBR28 DVR measures predict subsequent radiological progression of disease  
Baseline TSPO PET DVR measures from T2 hyperintense lesions, the NAWM and grey matter and changes 
in T2 lesions and whole brain or grey matter volume over 1 year were assessed for each patient (Table 2). 
The baseline NAWM DVR and the MRI volume measures at baseline and longitudinally are summarised in 
Table 2.  NAWM and white matter lesion DVR were positively correlated with enlarging T2 lesion volume 
(ρ=0.59, p=0.01; ρ=0.64, p=0.004, respectively) over the subsequent 1 year. A post hoc analysis suggested 
that this relationship was specific for the sub-group of patients with RRMS, who showed strong 
relationships between both baseline NAWM and white matter lesion DVR and enlarging T2 lesion volumes 
(ρ=0.74, p=0.008; ρ=0.64, p=1x10
-3
, respectively) (Figure 2A). By contrast, we did not find the associations 
between either the enlarging T2 lesion volume and NAWM DVR (ρ= -0.05, p=0.91) or white matter lesion 
DVR (ρ= -0.41, p=0.36) in the sub-group of SPMS patients ). However, correlations were observed in the 
SPMS patients between white matter lesion DVR and both subsequent changes in whole brain (ρ=0.86, 
p=0.04) and grey matter (ρ=0.96, p=5x10
-4
) volumes (Figure 2B). A trend towards correlation between 
NAWM DVR and whole brain volume change over the subsequent 1 year also was found in the SPMS 
patients (ρ=0.71, p=0.07) as part of this post hoc exploratory analysis, although it did not reach statistical 
significance. A similar analysis for the RRMS group did not identify associations between DVR and either 
whole brain or grey matter volume changes.  
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NAWM and white matter lesion DVR at baseline were not associated with total T2 lesion volume 
changes (the mean of contributions from both enlarging and shrinking lesions) between baseline and follow-
up (Spearman’s ρ= -0.08, p=0.75 and ρ= -0.01, p=0.95, respectively), nor were there significant associations 
between DVR and the total T2 lesion volume change in either the RRMS or SPMS sub-groups. We also did 
not find evidence for associations between NAWM and white matter lesion DVR at baseline and subsequent 
changes in whole brain (ρ= -0.006 p=0.98; ρ=0.08; ρ=0.74, respectively) or total grey matter (ρ=0.07; 
ρ=0.78; ρ=0.15; ρ=0.51, respectively) volumes for the group of multiple sclerosis patients as a whole.  
 
Stratifying patients for enlarging T2 lesion activity using baseline NAWM [
11
C]PBR28 DVR  
We explored whether differences in NAWM DVR at baseline could be used to stratify patients at higher risk 
of enlarging T2 lesion volumes over the subsequent year. We estimated the optimal NAWM DVR 
discriminating higher and lower risk of enlarging T2 lesion volume by constructing an ROC curve with 
NAWM DVR as the test variable. The discriminant value of baseline NAWM DVR that best discriminated 
between patients with an enlarging, rather than a decreasing or stable, T2 lesion volume was determined: 
NAWM DVR cut-off of 1.10 maximised specificity (67%) and sensitivity (67%) for discriminating a >5% 
increase. With this discriminant, there was an approximately 30% greater relative increase in enlarging T2 
hyperintense volumes in the higher (median 4.8 mL, range 1.1-10.6 mL) than in the lower (median 6.8 mL, 
range 0.7-9.6 mL) NAWM DVR sub-group (p=0.04, Mann-Whitney test) (Figure 3).  
 
Multivariate models predicting subsequent changes in MRI measures of disease progression 
We explored models predicting future disease activity based on demographic, clinical and MRI data, as well 
as PET measures at baseline. We initially modelled the whole brain volume change between the baseline 
and follow-up MRI scans as a function of EDSS, age and gender (R
2
=0.48, p=0.01). Neither the baseline 
NAWM DVR (controlling for TSPO binding status) nor the baseline T2 lesion volume improved the main 
model (R2 change=0.09, p=0.26 and R2 change<0.01, p=0.97, respectively). Overall T2 lesion volume 
change was not predicted by either the main model with variables EDSS, age, gender (p=0.68) or any of the 
subsequent levels of the hierarchical model described in the Methods (R
2 
change=0.02, p=0.87). 
We then explored models of the enlarging T2 lesion volume. EDSS, age and gender alone did not predict 
future enlarging T2 lesion volume well (R2=0.33, p=0.14). Including the baseline NAWM DVR added 
significant explanatory power to the model (R2 change=0.37, p=0.004). A hierarchical regression model 
with the first level as NAWM DVR accounted for approximately 50% of the variance in enlarging T2 lesion 
volumes (R
2
=0.46, p=0.001). We additionally explored inclusion of the baseline T2 lesion volume (R
2
 
change=0.30, p=5x10
-6
) and NAWM MTR (R
2
 change=0.12, p=0.04) and found that it improved the model 
prediction.  
 
Correlations between baseline [
11
C]PBR28 DVR and MRI measures of disease burden 
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To place these longitudinal observations in context, we tested for correlations between the [
11
C]PBR28 DVR 
and MRI measures of disease burden at baseline, extending our previous observations (Datta et al., 2017). 
Both NAWM and white matter lesion DVR were positively correlated with the baseline T2 lesion volume 
(ρ=0.49, p=0.03 and ρ=0.63, p=0.002, respectively). The baseline NAWM MTR was negatively correlated 
with NAWM DVR (ρ= -0.69, p=8x10
-4
). NAWM and white matter lesion DVR were negatively correlated 
with baseline whole brain volume (ρ= -0.81, p=4x10
-5
 and ρ= -0.74, p=4x10
-4
, respectively). NAWM DVR 
was correlated with baseline normalised grey matter volume (ρ= -0.56, p=0.02) (Figure 4), but we did not 
find a statistically significant association between white matter lesion DVR and grey matter volume at 
baseline (ρ= -0.49, p=0.08).  
We also tested for relationships between [
11
C]PBR28 DVR inflammatory measures across tissue 
compartments in the PET scan conducted at baseline. NAWM DVR was correlated strongly with the mean 
DVR of T2 white matter lesions (Spearman’s ρ= 0.92, p=3x10
-10
) and the mean cortical (ρ= 0.93, p=1x10
-10
) 
and thalamic (ρ= 0.79, p=1x10
-5
) DVR (Figure 5).  
 
Discussion 
We investigated in vivo glial activation in the white matter of multiple sclerosis patients using the second 
generation TSPO ligand, [11C]PBR28, and its relationship to subsequent changes in MRI over 1 year. We 
found that the [
11
C]PBR28 DVR in NAWM was highly correlated with DVR in T2 white matter lesions, 
whole cortex and the thalamus. NAWM and white matter lesion DVR were correlated with T2 lesion 
volume and whole brain volume at baseline. Enlarging T2 lesions and brain atrophy rates have prognostic 
significance for development of disability progression in multiple sclerosis (Sormani et al., 2014). We found 
that the white matter [
11
C]PBR28 DVR at baseline was correlated with the subsequent enlarging T2 lesion 
volume. A model including baseline NAWM DVR and NAWM MTR significantly improved prediction of 
future disease activity (enlarging T2 lesion volume) over the subsequent year relative to that estimated using 
only clinical and conventional MRI measures. 
We found that patients with a higher level of glial activation in the NAWM had increased microglial 
activation in white matter lesions and grey matter volumes. While post mortem studies have found only a 
weak correlation between white matter and grey matter lesion volumes, these studies have not addressed the 
innate immune activation accompanying them (Calabrese et al., 2015). They also have not included 
consideration of the potentially extensive, dynamically evolving meningeal inflammation (Lucchinetti et al., 
2011; Popescu and Lucchinetti, 2012; Absinta et al., 2015). Previous in vivo TSPO PET studies have found 
evidence for diffuse glial activation in grey and white matter of multiple sclerosis patients, relative to 
healthy controls (Filippi et al., 2012; Politis et al., 2012; Colasanti et al., 2014; Rissanen et al., 2014; 
Giannetti et al., 2015; Datta et al., 2016; Datta et al., 2017). Common genetic and environmental factors 
may contribute to the expression of brain inflammation throughout the brain and, through this, to disease 
progression (Zivadinov et al., 2009; Mowry et al., 2012; Gourraud et al., 2013). The strong correlations in 
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innate immune activation across brain tissue compartments defined by TSPO radioligand binding suggest 
that it may be most useful to consider central nervous system-wide immune activation for understanding 
individual differences in disease severity or progression, rather than that in any single tissue compartment 
(either white or grey matter).  
We found correlations between baseline whole brain volume and T2 lesion load with both the 
[
11
C]PBR28 DVR in NAWM and in white matter T2 lesions. A previous TSPO PET study reported 
correlations of NAWM TSPO ligand binding with baseline brain volume measures in SPMS (Versijpt et al., 
2005). This and related associations identified in cross-sectional studies have been interpreted to suggest that 
the diffuse microglial activation either contributes causally- or reflects a response- to neuroaxonal loss. With 
a longitudinal design, we were able to investigate the associations between microglial activation and 
measures of inflammatory activity and neuroaxonal loss more directly. We found that a measure of higher 
levels of microglial activation was associated with a greater volume of subsequently enlarging lesions in the 
RRMS sub-group. By contrast, in the sub-group of patients with SPMS, microglial activation was associated 
not with enlarging T2 hyperintense lesions in the white matter, but with greater subsequent brain atrophy. A 
limitation of our study is that it was not powered to assess the multivariate hierarchical regression models 
separately for sub-groups of RRMS and SPMS patients. These associations also suggest that innate immune 
activation contributes to future inflammatory neurodegeneration, but do not rule out the possibility that the 
association is a response to neurodegeneration, rather than a cause. To test this confidently, longitudinal 
assessment of responses to an intervention that selectively modulates the diffuse microglial activation is 
needed.  
Nonetheless, there is evidence that some or all of the microglial activation measured here is contributing 
to neurodegeneration. Activated nodules of microglia have been detected in extra-lesional white matter both 
in association with demyelinating axons and in the absence of myelin loss (van Horssen et al., 2012; Singh 
et al., 2013). Pre-clinical studies support a role for microglial activation being pro-inflammatory in multiple 
sclerosis and contributing to neurodegeneration (see e.g., (Duffy et al., 2014)). More indirectly, Previous 
work suggested that white matter MTR as a sensitive in vivo marker of neurodegeneration (combined neuro-
axonal loss and demyelination) predicts future disease progression (Agosta et al., 2006). We found that 
[
11
C]PBR28 NAWM DVR was negatively correlated with NAWM MTR. We had observed this also in a 
previous study using another second generation TSPO ligand ([
18
F]PBR111), which showed higher TSPO 
binding in the NAWM with lower MTR (Colasanti et al., 2014).  
Short-term disability progression is predicted well by a combination of the whole brain atrophy rate and 
the numbers of new and enlarging T2 lesions over 6-12 months (Popescu et al., 2013; Sormani et al., 2014). 
Here we constructed a model for prediction of future disease activity based on NAWM DVR, NAWM MTR 
and T2 lesion volumes measured at a single time point. This model explained over 90% of the variance in 
enlarging lesion volumes over the subsequent 1 year. This is consistent with the hypothesized association 
between diffuse innate immune activation in white matter and new T2 lesions and histopathological 
Page 11 of 26
ScholarOne, 375 Greenbrier Drive, Charlottesville, VA, 22901  Support (434) 964 4100
Brain
For Peer Review
 12
interpretations of white matter lesions having prominent microglial activation at their edges as enlarging 
lesions (Lucchinetti et al., 2004; Filippi et al., 2012).  
There are limitations to our study. First, feasibility limited the number of patients. Our study also 
included a mixed population of multiple sclerosis patients (many of who were receiving disease modifying 
treatments) with a follow-up of approximately 1 year. The group of RRMS patients was very heterogenous 
(EDSS from 1 to 7 and DD from 1 to 28 years). With the smaller population size and short duration of 
follow-up, we did not detect any new T2 lesions and there were few relapses and little overall EDSS change 
across the group. This is not uncommon with relatively short follow-up periods for patients on treatment 
(Goldman et al., 2010). We did not attempt to directly assess relationships between microglial activation and 
the appearance of new lesions in the grey matter, as 3Tesla MRI appears relatively insensitive to cortical 
lesions (Geurts et al., 2005; Klaver et al., 2013). This question may be better addressed in the future using 
ultra-high MRI (Klaver et al., 2013). We also did not compare the longitudinal changes in brain volumes 
between MS patients and well-matched healthy volunteers, although it is well established that regional and 
global brain atrophy rates are greater in MS patients than healthy people (Barkhof et al., 2009). A future 
study including healthy volunteersubjects or an appropriate healthy, historical comparator group also would 
enhance the clinical meaningful of observations by testing directly whether increased microglial activation is 
associated with rates of brain atrophy in patients that are significantly greater than in a matched healthy 
control group. Finally, our conclusions regarding differential responses in the sub-groups with RRMS and 
SPMS were based on post hoc analyses. TSPO PET studies including larger numbers of progressive 
multiple sclerosis patients and patients of longer duration are needed. Further analysis focusing on 
individual lesional [
11
C]PBR28 DVR and MTR could provide insights into how microglial activation relates 
to future changes in the balance of remyelination and demyelination within individual lesion volumes. 
Available neuropathology and a recent combined magnetic resonance spectroscopic and TSPO PET study 
suggest that microglial activation likely makes the dominant contribution to the higher TSPO PET signal in 
people with multiple sclerosis (Matthews and Datta, 2015; Datta et al., 2016). Our results demonstrate 
strong correlations between the diffuse glial activation measured by TSPO PET in white and grey matter, 
despite the lack of a strong association between focal lesional activity in white and grey matter (Bo et al., 
2007). While we cannot be confident of the mechanisms mediating the relationships observed, our results 
provide evidence that the microglial activation assessed by TSPO is meaningful clinically. Our study 
suggests that greater activation in the NAWM is a marker of greater risk of subsequent enlarging lesions in 
RRMS patients and, in patients with SPMS, greater future brain atrophy. Both of these imaging 
neuropathological changes are associated with disability progression.  
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Figure legends 
Figure 1. Illustrative parametric brain PET [
11
C]PBR28 distribution volume ratio (DVR) images at baseline 
(A, D) from two patients with associated T2 FLAIR images at baseline (B, E) and after approximately 1 
year (C, F). The top panels (A-C) are from a patient (EDSS 4.0) with high average normal appearing white 
matter (NAWM) DVR (1.35) (patient MS10 in Table 1). The yellow arrowhead highlights a lesion that 
enlarged over the observation interval. The bottom panels (D-F) include images from a patient (EDSS 6.0) 
with low average NAWM DVR (0.88) for whom no enlarging T2 lesions were found between the baseline 
(E) and follow up (F) MRI scans (patient MS17 in Table 1). The colour bar to the right of the PET images 
shows the dynamic range of DVR in the images (A, D). 
 
Figure 2.  Plots of T2 white matter lesions (WML) [
11
C]PBR28 distribution volume ratio (DVR) against (A) 
enlarging T2 WML volume change in relapsing remitting multiple sclerosis patients (RRMS)  and (B) either 
normalised whole brain volume (WBV) atrophy rate or grey matter volume (GMV) atrophy rate in 
secondary progressive disease (SPMS). The dotted line (A) is the best fit line for the RRMS patients 
(Spearman’s ρ=0.64, p=1x10
-3
). The unbroken regression line is for GMV atrophy (ρ=0.96, p=5x10
-4
) and 
the dashed line is for WBV atrophy (ρ=0.86, p=0.04) in SPMS patients (B).  
 
Figure 3. Boxplot of the enlarging T2 white matter lesion volume over 1 year of follow up of the multiple 
sclerosis patients stratified by low (<1.10) and high (>1.10) [
11
C]PBR28 distribution volume ratio (DVR) in 
the normal appearing white matter (NAWM) at baseline (p=0.04). 
 
Figure 4. At baseline, the white matter [
11
C]PBR28 distribution volume ratios (DVR) are correlated with 
MRI whole brain and grey matter volumes. (A) Normal appearing white matter (NAWM) DVR against 
baseline WBV (Spearman’s ρ= -0.81, p=4x10
-5
). (B) White matter lesions (WML) DVR against baseline 
WBV (ρ= -0.74, p=4x10-4). (C) NAWM DVR against baseline grey matter (GM) volume (ρ= -0.56, p=0.02). 
(D) WML DVR against baseline GM volume (ρ= -0.42, p=0.08). 
 
Figure 5. Plots of normal appearing white matter (NAWM) [
11
C]PBR28 distribution volume ratio (DVR) 
against (A) T2 white matter lesion (WML) DVR (Spearman’s ρ= 0.92, p=1x10-10), (B) cortical DVR (ρ= 
0.93, p=4x10-11) and (C) thalamic DVR (ρ= 0.79, p=4x10-6).  
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TABLE 1. Clinical demographics of individual multiple sclerosis patientsubjects. Relapses ,and EDSS change and medication change refer to the time period 
between baseline and 1 year follow-up visits. Disease duration is the time between the manifestation of patient’s first symptoms and the date of MRI 
examination. The baseline characteristics of these patients have been described in a recent report (Datta et al., 2017). Age and disease duration refer to the time 
of the baseline visit. Abbreviations: MS = multiple sclerosis; F = female; M = male; RRMS = relapsing remitting multiple sclerosis; SPMS = secondary 
progressive multiple sclerosis; DMT = disease modifying treatment. Three patients (grey) were assessed only at the baseline, as described earlier (Datta et al., 
2017) and were not included in the longitudinal follow up of this cohort that is described in this report. 
 
Patient Gender Age (years) MS subtype Disease 
duration 
(years) 
Baseline 
EDSS 
Follow-up 
EDSS 
EDSS 
change 
Relapses DMT treatment at follow-up (changes from 
baseline are noted) 
A1 F 22 RRMS 16 3.0 3.5 0.5 3 Fingolimod 
A2 M 38 RRMS 10 6.0 6.5 0.5 0 Alemtuzimab 
A3 F 42 RRMS 13 1.0 1.0 0 0 Nataluzimab 
A4 F 50 RRMS 9 2.5 2.0 -0.5 1 None 
A5 M 59 SPMS 23 6.0 6.0 0 0 None 
A6 M 36 RRMS 6 1.0 1.0 0 1 Dimethyl fumarate 
A7 F 57 RRMS 18 1.0 1.0 0 1 Fingolimod 
A8 M 48 RRMS 12 7.0 7.0 0 0 Nataluzimab 
A9 M 53 RRMS 14 5.0 Nataluzimab 
A10 M 43 SPMS 13 5.0 5.0 0 0 None 
A11 F 29 RRMS 1 1.0 1.0 0 0 None (interferon β was discontinued 6 months 
before follow-up) 
A12 F 51 RRMS 8 6.5 6.5 0 1 Nataluzimab 
A13 F 62 SPMS 24 6.0 6.0 0 0 None 
A14 M 56 SPMS 17 7.0 7.0 0 0 None 
A15 F 52 RRMS 6 2.0 1.5 -0.5 0 Alemtuzimab 
A16 F 45 RRMS 28 4.0 4.0 0 0 Alemtuzimab 
A17 F 66 SPMS 17 6.5 7.5 1 0 None 
A18 F 53 RRMS 16 3.0 3.0 0 0 None 
A19 F 30 RRMS 6 4.0 5.5 1.5 1 None (nataluzimab was discontinued 9 months 
before follow-up visit) 
A20 M 36 SPMS 10 7.0 7.0 0 0 None 
A21 M 47 SPMS 11 7.0 8.0 1 0 None 
A22 M 39 RRMS 10 4.0 Alemtuzimab 
A23 F 45 RRMS 14 6.5 Fingolimod 
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A24 F 64 RRMS 22 2.5 3.0 0.5 0 Nataluzimab 
          TABLE 2. MRI brain volume characteristics of individual multiple sclerosis patientssubjects. Abbreviations: NAWM = normal appearing white matter; MS = 
multiple sclerosis; WBV = whole brain volume (normalised); GMV = grey matter volume (normalised); T2 WML = T2-weighted white matter lesions.  Three 
patients (grey) were assessed only at the baseline, as described earlier (Datta et al., 2017) and were not included in the longitudinal follow up of this cohort that 
is described in this report. 
 
Patient  
[11
C]PBR28 
NAWM DVR 
Baseline 
WBV (cm
3
) 
Follow-up 
WBV (cm
3
) 
WBV 
change (%) 
Baseline 
GMV (cm
3
) 
Follow-up 
GMV (cm
3
) 
GMV 
change (%) 
Baseline T2 
WML volume 
(mL) 
T2 WML 
volume 
change (mL) 
Enlarging T2 
WML volume 
change (mL) 
A1 0.80 1505 1493 -0.85 910 906 -1.2 4.6 -0.1 0.2 
A2 0.81 1529 1537 0.56 901 902 0.71 1.5 0.0 0.2 
A3 0.82 1544 1531 -0.3 926 915 -0.14 5.4 -0.1 0.1 
A4 0.87 1489 1485 0.16 917 907 -0.19 2.2 -0.1 0.1 
A5 0.88 1422 1407 -0.16 842 831 -0.5 6.2 -0.3 0.3 
A6 0.94 1500 1505 0.5 940 937 0.72 6.1 -0.2 0.1 
A7 0.97 1467 1465 -0.52 898 894 -0.6 2.0 -0.1 0.0 
A8 1.03 1408 1410 0.57 865 859 0.38 14.9 0.2 0.3 
A9 1.07 1403   838   23.4   
A10 1.07 1448 1433 0.11 849 839 0.13 9.8 -0.3 0.4 
A11 1.08 1524 1513 -0.13 922 914 -0.18 8.2 -0.9 0.5 
A12 1.09 1399 1412 -0.78 871 878 -1.21 4.7 -0.4 0.1 
A13 1.11 1388 1390 -0.21 832 830 0.09 8.0 -0.2 0.6 
A14 1.12 1395 1392 0.21 862 850 0.19 5.8 -0.2 0.2 
A15 1.16 1477 1478 0.21 859 856 -0.05 13.8 -1.2 0.7 
A16 1.20 1424 1417 -0.12 873 866 0.11 29.5 -1.9 2.8 
A17 1.29 1390 1372 0.02 820 805 -0.28 36.7 2.2 2.3 
A18 1.32 1431 1426 -0.5 899 888 -0.8 15.4 -0.7 0.8 
A19 1.35 1383 1366 -1.39 843 838 -0.68 26.7 0.6 1.6 
A20 1.38 1337 1370 1.45 838 860 2.44 20.6 -0.6 0.1 
A21 1.51 1341 1343 0.5 803 821 1.88 8.3 0.2 0.4 
A22 1.67 1361   842   38.1   
A23 1.68 1440   903   2.3   
A24 1.85 1251 1246 -0.61 790 789 -0.52 36.6 0.5 3.4 
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Figure 5  
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